Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Oppenheimer Downgrades Relmada Therapeutics to Perform

Oppenheimer analyst Jay Olson downgrades Relmada Therapeutics (NASDAQ:RLMD) from Outperform to Perform.
byBenzinga Newsdesk
October 13, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Oppenheimer analyst Jay Olson downgrades Relmada Therapeutics (NASDAQ:RLMD) from Outperform to Perform.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts